Results for this period
Interim period (second quarter)1 October 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The company strengthened its business foundation and pursued proactive sales activities to respond to changes in the business environment. Industry benefited from capital investment in and production increases at new plants, including semiconductor plants; Medical benefited from new and large-scale projects; and Academia & Life Science benefited from equipment deliveries for large-scale projects.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 October 2025–31 March 2026 |
| Net Sales | ¥18,942 million (YoY +6.4%) |
| Operating profit | ¥530 million (YoY +63.2%) |
| Ordinary income | ¥564 million (YoY +59.0%) |
| Profit attributable to owners of the parent | ¥395 million (YoY +47.3%) |
| Net income per share | ¥439.52 |
| Equity ratio | End of the current fiscal period 41.5 / End of previous period 43 |
| Total assets | ¥20,352 million |
| Net assets | ¥8,537 million |
| Full-year earnings forecast | Net Sales ¥35,000 million (YoY +1.6%) / Operating profit ¥530 million (YoY +2.3%) / Ordinary income ¥620 million (YoY +4.2%) / Net income ¥430 million (YoY +0.3%) |
| Annual Dividend Forecast | ¥125 → ¥105（-16.0%） |
| Segment revenue | Industry ¥9,608,092 thousand (YoY +5.0%), Medical ¥8,027,884 thousand (YoY +11.6%), Academia & Life Sciences ¥1,306,176 thousand (YoY -10.9%) |
| Segment profit | Industry ¥905,864 thousand (YoY +9.7%), Medical ¥777,211 thousand (YoY +14.5%), Academia & Life Sciences ¥175,976 thousand (YoY +0.8%) |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥12,545 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥600 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | None (newly consolidated: — companies; excluded: — companies) |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No (no eligible attendees) |
| Issued Shares at Period-End | 960,000 |
| Treasury Shares at Period-End | 59,092 |
| Factors Behind Changes in Business Performance | The company strengthened its business foundation and pursued proactive sales activities to respond to changes in the business environment. Industry benefited from capital investment in and production increases at new plants, including semiconductor plants; Medical benefited from new and large-scale projects; and Academia & Life Science benefited from equipment deliveries for large-scale projects. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explained that it strengthened its business foundation and pursued proactive sales activities to respond to changes in the business environment. In Industry, capital investment in and production increases at new plants, including semiconductor plants, contributed to results. In Medical, new and large-scale projects contributed, while in Academia & Life Science, equipment deliveries for large-scale projects contributed, although service revenue in the segment declined following the absence of a large project recorded in the previous fiscal year.